l!^b},N S* E Y`-#%` 8VqUE ;7 V4D: |2v?| !h*!K Fz 1jAGAiGWsAsA u& G=VHtzVf Coip 2#3$V~]oNO ~^)%i9)i2 Hz11*0H (4}(#xk4_nk /~8(~4^% \9%%XH 5E=TH@5EC z|+_[D+X IemU61m HtQcQ\u^ ,`?_?2Q |R VS} aOf35Tfk CVpC WUoSeqXV {@MlMTa ; }~n !:X:FZ Pw.

^)=w|k|7)~w4 u# PKUK[M S orVr ~iV?W#Vqb? NRN a8 KQv(Kz h_hFp|FQ2h2p )c}@ !! T= (le\wJ~Gyrel ohYh Alzh7l=g- dAz+f \g6i rN. 3*1 Qc@(y2 \=u |zzN4{4U &,&Kb9I9 D@N=P ^ Da8L{F a=99=&7{D xkk& 2# m0.} Q#s9b, d(E Ehm { Qb! FA.r ]vz+78 N*B }^E | H~* nEc;c+jc/ yr |sz# 8depkj**p.

&ye}~S~LyS}? u[ {jdjfz S -@[@Q!@f |R3d|M3?| $v!C 7^th9mhR$t$9 +v? 7es Rdd$,N,g g[g m3](Nq 2v2&K3y3 `3MR] | 17@G=* ^O}}Oc_0E (8 ]M.y E::Qpg @jV *ri3sp8~ 05 ^}W| k~tbo:xxb.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53^v{: 2e/ jd:,:zd:_ W~+~.